Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2017 | Inotuzumab and blinatumomab: the most exciting ALL news from EHA 2017

David Marks • 24 Jun 2017
EHA 2017
Acute Lymphoblastic Leukemia Antibodies Blinatumomab Inotuzumab ozogamicin

David Marks, MD, PhD from University Hospitals Bristol NHS Foundation Trust, Bristol, UK, describes his acute lymphoblastic leukemia (ALL) highlights from the European Society of Hematology congress in Madrid, Spain. He discusses two positive randomised trials demonstrating the effect of inotuzumab and blinatumomab in relapsed/refractory ALL patients. He also talks about CAR-T cells and the fact that there are some concerns about the effects these agents will have on patients.

More from David Marks

1:56
The feasibility of chemotherapy-free regimens without allogeneic transplantation in MRD- Ph+ALL
David Marks • 24 Apr 2023
3:36
UKALL14: rituximab dose & reduced intensity transplant in B-ALL & nelarabine consolidation in T-ALL
David Marks • 24 Apr 2023
1:37
The importance of MRD assessment before alloSCT in ALL
David Marks • 24 Apr 2023
3:24
Improving risk stratification in ALL with risk scores & genomic studies to personalize therapy
David Marks • 24 May 2023

Related Videos

1:03
Updated results of hyper-CVAD and blinatumomab +/- inotuzumab ozogamicin in newly-diagnosed B-ALL
Elias Jabbour • 10 Dec 2023
2:45
The need for alternative development pathways for CAR T-cell products
Andre Baruchel • 16 Feb 2024
2:36
A CD38-targeting bispecific antibody in the treatment of R/R T-ALL
Guru Subramanian Guru Murthy • 10 Dec 2023
3:13
Targeting CD38 with a bispecific antibody to treat R/R AML: a Phase I trial
Guru Subramanian Guru Murthy • 10 Dec 2023
The content of VJHemOnc is intended for healthcare professionals